Analyst Downgrades Sequenom; New Benefits Provider Covering MaterniT21 Plus | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray today downgraded Sequenom's shares, citing increasing competition, as well as pricing pressures and legal concerns.

Separately, after the close of the market on Thursday, Sequenom said that its subsidiary, Sequenom Laboratories, has signed a national agreement with an unnamed "leading benefits provider" to provide coverage for the MaterniT21 Plus fetal aneuploidy test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.